SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024
SI-BONE (NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 4,000 surgeons in performing more than 110,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 140 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
加利福尼亞州聖克拉拉，2024年11月20日（全球新聞稿）——si-bone公司（納斯達克：SIBN），是一家致力於解決骶髖疾病的醫療器械公司，今天宣佈公司將參加即將在紐約舉行的派傑投資醫療會議。管理層將在2024年12月4日星期三東部時間上午11:00 / 太平洋時間上午8:00舉行一次爐邊談話。
Investors interested in listening to the conference call may do so by registering at this link: . Live audio of the webcast will be available on the "Investors" section of the company's website at: . The webcast will be archived and available for replay for at least 90 days after the event.
有興趣收聽電話會議的投資者可以通過此鏈接註冊。網絡直播的實時音頻將在該公司網站的「投資者」版塊上提供。網絡直播將被存檔並可在活動結束後至少90天內重播。
About SI-BONE, Inc.
SI-BONE, Inc.是全球領先的骶骨盆腔解剖學肌肉骨骼疾病外科治療技術公司（NASDAQ:SIBN）。自2009年在SI關節的微創手術方面開創先河以來，SI-BONE支持超過3700名外科醫生進行了超過100,000次的骶骨盆腔手術。一系列獨特的臨床證據支持SI-BONE的技術，包括四個隨機對照試驗和超過130篇同行評審出版物。SI-BONE利用其在微創椎盤融合方面的領導地位，推出了鄰近市場的新解決方案，包括成人畸形，脊骨盆固定和盆腔創傷。
SI-BONE (NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 4,000 surgeons in performing more than 110,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including two randomized controlled trials and over 140 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
si-bone（納斯達克：SIBN）是全球領先的骶髖疾病外科治療科技公司。自2009年首創si關節的微創手術以來，si-bone已支持超過4,000名外科醫生進行超過110,000例骶髖手術。獨特的臨床證據支持si-bone技術的使用，包括兩項隨機對照試驗和超過140篇經過同行評審的出版物。si-bone利用其在微創si關節融合方面的領導地位，開發出針對相鄰市場的新穎解決方案，包括成人畸形、脊骨盆固定和骨盆創傷。
For additional information on the company or the products including risks and benefits, please visit .
iFuse Bedrock Granite，iFuse-TORQ，SI-BONE和iFuse INTRA是SI-BONE, Inc.的註冊商標。 2024年SI-BONE，Inc.版權所有。
iFuse Bedrock Granite, iFuse-TORQ, iFuse TORQ TNT, SI-BONE, and iFuse INTRA are registered trademarks of SI-BONE, Inc. 2024 SI-BONE, Inc. All Rights Reserved.
iFuse Bedrock Granite、iFuse-TORQ、iFuse TORQ TNt、si-bone以及iFuse INTRA是si-bone公司的註冊商標。2024 si-bone公司。保留所有權利。
Investor Contact: Saqib Iqbal investors@si-bone.com
投資者聯繫人：Saqib Iqbal investors@si-bone.com
譯文內容由第三人軟體翻譯。
